ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MTFB Motif Bio Plc

0.50
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.50 0.40 0.55 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Motif Bio Share Discussion Threads

Showing 676 to 697 of 9925 messages
Chat Pages: Latest  37  36  35  34  33  32  31  30  29  28  27  26  Older
DateSubjectAuthorDiscuss
25/11/2015
09:44
There's a new Interview with Graham Lumsden on Directors talk, see link below::


Graham Lumsden chats to DirectorsTalk about the Phase III Clinical Trials 80mg fixed dose. Graham explains why a fixed dose is important, how this benefits the company, patients and clients and how the 80mg dose was determined.

timbo003
24/11/2015
08:45
Another positive RNS....but will we finish RED.
regandharry5
24/11/2015
07:56
AH. R eceipt of FDA Concurrence with Optimized Dose for Iclaprim Phase III Clinical Trials.
hazl
11/11/2015
12:54
Another positive RNS but will we finish red...Don't you just love these MMs.
regandharry5
11/11/2015
08:54
Northlands have reiterated fair value of 114p,Its closest peer
Nasdaq listed Paratek trades at a substantial premium to northlands
target price for motif,if approved could achieve a $1billion a year
in sales.

victor2
11/11/2015
08:10
everything's quietly happening in the background.........
hazl
11/11/2015
08:01
I see they are going for the centralized procedure in Europe, excellent!
timbo003
11/11/2015
07:50
Steady progress through the regulatory maze .....
small crow
27/10/2015
07:55
Ah! Selected to present at Bio-Europe.
hazl
17/10/2015
16:44
Thanks Proactive, link to video now in the header

It was a bit of a left field question at the end I thought!

timbo003
16/10/2015
14:48
Video interview with CEO Lumsden



Graham Lumsden, chief executive at Motif Bio (LON:MTFB), says the tie-up with contract research organisation Covance is critical in de-risking the final stage clinical trials of Motif’s flagship drug iclaprim.

Covance will run two phase-III studies on iclaprim to assess whether it is better than existing treatments for tackling bacteria that are resistant to traditional antibiotics.

Motif aims to market iclaprim in 2018 and Lumsden says there will be 10 years of market exclusivity meaning no generic competition until at least 2028. He anticipates a similar protection period in Europe.

proactivest
16/10/2015
09:02
yes you can feel the momentum building imo
hazl
16/10/2015
06:18
Excellent partner announced this am.
small crow
13/10/2015
09:08
Don't like the sound of 'infectious diseases week'!

Seriously,though,its going in the right direction here.

IMO

hazl
13/10/2015
06:34
This is looking poised for further gains
gersemi
05/10/2015
16:06
Directors buy...60K worth. Shows confidence.
regandharry5
30/9/2015
09:07
There's some new Broker comment (Beaufort) published this morning on the proactive web site:
timbo003
29/9/2015
08:38
Hilarys tweet about the pharma sector,in general has not helped us,I'm afraid.
Will retain a small holding.

hazl
28/9/2015
13:01
Thanks very much indeed timbo
hazl
28/9/2015
12:27
See below a few supplementary notes on Graham Lumsden’s presentation at the proactiveinvestors meeting last Thursday:

During the presentation GL made several references to Motif’s market cap vs comparable companies in the US and said it was the director’s objective to close the valuation gap (possibly with a Nasdaq listing). He cited Paratek a couple of times as a good example of the valuation gap. Paratek is a Nasdaq listed small pharma specialising in antibiotics with one just main clinical asset (Omadacyclin) which is currently in phase III studies and running about 1 year ahead of Motif’s Iclaprim. Paratek’s market cap is around $400m compared to Motif’s market cap of around $115m (or $150m fully diluted)




The other comparitors mentioned were Durata, Cempra and Tetraphase

He emphasised that Motif need around £35m for the phase III clinicals and they already have £25m and added that the additional funding could come from various sources, he spent time discussing two such routes:
1) an equity raise (at the right price) and I assume they have a Nasdaq listing in mind for this option.
2) up-front fee from a partnership for a particular geographical region (not the US), with a regional deal for a drug of Ipraclim’s potential normally commanding an upfront fee of around 10 – 15m.

Motif had discussions concerning the phase III clinicals for Iclaprim with the Netherlands regulators last week (the Netherlands are presumably the rapporteurs for Europe submission) and have agreement on the proposed clinical trial program. Motif will be granted 10 years exclusivity on the regulatory data within Europe (which is basically as good as having 10 years extra patent life).

When GL talked about Iclaprim’s mechanism of action, he placed particular emphasis on its unusually good tissue penetration and the fact that unlike most other antibiotics there was no need to adjust the dose when there were other co-morbidities accompanying bacterial infection, which is one of the reasons why an oral dosage form for Iclaprim would be particularly useful.

GL spent some time discussing the near term pipeline. One project they are particularly keen to progress is to develop an orally administered dosage form for Iclaprim. This would be particularly useful where prolonged antibiotic dosing is required and especially for indications where deep tissue penetration is desirable. Graham cited Osteomylitis as a target indication for oral iclaprim:


Osteomyelitis requires antibiotic dosing over a period of 6 weeks (too long a period for IV administration) and iclaprim shows particularly good penetration into bone tissue compared to many other antibiotics (Note it also shows exceptional penetration into lung tissue hence its use in HABP) . Oral Iclaprim may only require one phase II study in Osteoyelitis for approval, assuming the phase III program on the iv formulation for HABP and ASSSI has been successful.

GL mentioned 4 other in licencing pipeline opportunities (see slide 19), but singled out one of them that was of particular interest as it would complement Iclaprim for the treatment of HABP (which can be caused my multiple different pathogens) he opined that this particular candidate may get initial approval with minimal clinical data (phase II studies).

I spoke to GL after the meeting and introduced myself as one of the fortunate few who had managed to buy a few shares in the IPO, adding that I had since topped up in my SIPP (at around 50p). He congratulated me on getting some in the IPO, I asked why so few shares were issued at the IPO and why the price was so low. He said that the main objective of the IPO was to get a listing (raising substantial funds seems to be a secondary objective). If they had not got a listing when they did, they would have lost Iclaprim, so it was essential to get the IPO away extremely quickly and at short notice. That certainly reflects my own experience, the only information I received on Motif was a slide set on Feb 26th lunchtime, I then had to make a decision on whether to apply on the same day and have funds available on account in order to proceed.

timbo003
25/9/2015
11:18
It was a good meeting last night and there is a new interview with Graham Lumsden over on the Proactive Website along with the slide set from last nights presentation






I will add a few additional thoughts later but have an AGM write up (SDI) from earlier this week to do first.

timbo003
24/9/2015
10:32
I'll be going along tonight, anyone else planning to attend?
timbo003
Chat Pages: Latest  37  36  35  34  33  32  31  30  29  28  27  26  Older

Your Recent History

Delayed Upgrade Clock